Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from a top five pharmaceutical company for renewed and expanded global licenses for Simulations Plus software.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “Like our announcement of the renewal last week, this company’s scientists have also been among our longest-standing users and have provided numerous suggestions for improving GastroPlus over the years. Feedback from our users at this customer’s research sites indicates that GastroPlus is playing an increasing role in studies during preclinical development, including helping to determine first dose amounts in human – a critical decision prior to conducting Phase I trials.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “This new license is a renewal of the global license that slipped from the first quarter to the second quarter last year. Because this renewal again comes in the second quarter, it adds to the large order announced last week which means that pharmaceutical software and services revenues for the second quarter of this fiscal year already significantly exceed last year’s record second quarter. I would also like to take this opportunity to wish all of our shareholders a very happy and safe holiday season and new year.”

The Company’s second fiscal quarter will end on February 28.